Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

ATG001

Sigma-Aldrich

Raji CD19 Antigen Panel Cell Lines

human lymph (lymphoblast), lymphoblast

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
41106514
NACRES:
NA.41

product name

Raji CD19 Antigen Panel Cell Lines,

Origine biologica

human lymph (lymphoblast)

Modalità di accrescimento

suspension

Morfologia

lymphoblast

Condizioni di spedizione

dry ice

Temperatura di conservazione

−196°C

Descrizione generale

This product is a panel of three (3) genetically modified cell lines involving the CD19 gene. The panel consists of a CD19 knockout cell line (CD19-/-) as well as a CD19low and a CD19high expression cell line. The CD19-/- cell line was generated using CompoZr® Zinc Finger Nuclease technology, and the two CD19 expression cell lines were generated using MISSION® lentivirus. The CD19low and CD19high cell lines express CD19 at low and high levels relative to the CD19-/- cell line (CD19high > CD19low > CD19-/-) as measured via fluorescence-activated cell sorting (FACS). As a comparison, wild type Raji cells demonstrate CD19medium expression as measured via FACS.

The STR profile of these cell lines match that of its parental cell line - ECACC catalog number 85011429.

Descrizione della linea cellulare

Established in 1963 from Burkitt′s lymphoma in an 11 year old male. Growth is in the form of single cells without attachment and as macroscopically visible clumps containing many hundreds of cells. Resistant to VSV. This cell line carries the latent Epstein-Barr Virus (EBV) genome and is positive for EBNA. Raji is sometimes referred to as a ′non-producer′; the EBV genome carries deletions attributed to preventing the formation of virus particles. Ethnicity: Black

Caratteristiche e vantaggi

The Raji CD19 antigen panel cell lines feature CD19 expressed at varying levels (KO, low, and high). These cell lines enable researchers to screen and evaluate the binding and potency of CD19-targeted immunotherapies in a biologically-relevant cellular research model.

Componenti

ATG001A-1VL: Raji CD19 Knockout
ATG001B-1VL: Raji CD19 Low
ATG001C-1VL: Raji CD19 High

Qualità

Tested for Mycoplasma, bacterial and fungal content, post-freeze viability, and short terminal repeat (STR) analysis for cell line identification.

Note legali

CompoZr is a registered trademark of Merck KGaA, Darmstadt, Germany
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Codice della classe di stoccaggio

10 - Combustible liquids


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Articoli

Whether you need screening tools for CAR/TCR therapies and mAB development, target cells for efficacy testing, or potency assays for clinical development, we provide functional biologically-relevant solutions to help you save time, accelerate your immuno-oncology research, and simplify your workflow.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.